drugset / Trial / NCT04136444

A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function

NCT04136444

Phase 1 Terminated 12 enrolled UCB Biopharma S.P.R.L.
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of the study is to evaluate the plasma pharmacokinetic (PK), safety and tolerability of padsevonil (PSL) in hepatically impaired and non-hepatically impaired study participants.

Timeline

Start
2019-10-28
Primary completion
2020-05-22
Completion
2020-05-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Padsevonil Small molecule

Indications

No indication recorded.